NASDAQ:IRMD - Iradimed Stock Price, News & Analysis

$23.09
+0.05 (+0.22 %)
(As of 09/16/2019 04:00 PM ET)
Today's Range
$21.15
Now: $23.09
$23.22
50-Day Range
$18.29
MA: $20.65
$23.97
52-Week Range
$16.68
Now: $23.09
$38.78
Volume78,596 shs
Average Volume68,715 shs
Market Capitalization$262.53 million
P/E Ratio53.70
Dividend YieldN/A
Beta1.67
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.44 million
Cash Flow$0.6608 per share
Book Value$3.84 per share

Profitability

Net Income$6.30 million

Miscellaneous

Employees95
Market Cap$262.53 million
Next Earnings Date10/29/2019 (Estimated)
OptionableNot Optionable

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.


Iradimed (NASDAQ:IRMD) Frequently Asked Questions

What is Iradimed's stock symbol?

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

How were Iradimed's earnings last quarter?

Iradimed Corp (NASDAQ:IRMD) posted its earnings results on Tuesday, October, 30th. The medical equipment provider reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The medical equipment provider had revenue of $7.62 million for the quarter, compared to analysts' expectations of $7.43 million. Iradimed had a net margin of 23.92% and a return on equity of 14.78%. View Iradimed's Earnings History.

When is Iradimed's next earnings date?

Iradimed is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Iradimed.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed issued an update on its third quarter 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share guidance of $0.14-0.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.16. The company issued revenue guidance of $9.7-10 million, compared to the consensus revenue estimate of $9.84 million.

What price target have analysts set for IRMD?

1 Wall Street analysts have issued 12-month target prices for Iradimed's shares. Their predictions range from $35.00 to $35.00. On average, they expect Iradimed's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 51.6% from the stock's current price. View Analyst Price Targets for Iradimed.

What is the consensus analysts' recommendation for Iradimed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.

Has Iradimed been receiving favorable news coverage?

Media stories about IRMD stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iradimed earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Iradimed.

Are investors shorting Iradimed?

Iradimed saw a decrease in short interest during the month of August. As of August 15th, there was short interest totalling 457,700 shares, a decrease of 13.2% from the July 15th total of 527,200 shares. Based on an average daily trading volume, of 78,800 shares, the short-interest ratio is presently 5.8 days. Approximately 9.3% of the shares of the stock are short sold. View Iradimed's Current Options Chain.

Who are some of Iradimed's key competitors?

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), Micron Technology (MU), Palo Alto Networks (PANW), BioTelemetry (BEAT), Cisco Systems (CSCO), Alphabet (GOOG), IntriCon (IIN), GrubHub (GRUB) and Mastercard (MA).

Who are Iradimed's key executives?

Iradimed's management team includes the folowing people:
  • Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Christopher K. Scott, CFO & Sec. (Age 49)
  • Mr. John McCreery, Chief Operating Officer (Age 64)
  • Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
  • Mr. Louis Waldman, Controller (Age 64)

Who are Iradimed's major shareholders?

Iradimed's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Atria Investments LLC (6.92%), Atria Investments LLC (6.79%), BlackRock Inc. (3.44%), Renaissance Technologies LLC (3.20%), Vanguard Group Inc. (2.43%) and RK Capital Management LLC (1.70%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

Which major investors are selling Iradimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Acadian Asset Management LLC, Victory Capital Management Inc., Cadence Capital Management LLC, LPL Financial LLC, GSA Capital Partners LLP, Fiera Capital Corp and Wells Fargo & Company MN. Company insiders that have sold Iradimed company stock in the last year include Brent Johnson, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.

Which major investors are buying Iradimed stock?

IRMD stock was bought by a variety of institutional investors in the last quarter, including Atria Investments LLC, Atria Investments LLC, Marshall Wace LLP, RK Capital Management LLC, BlackRock Inc., Mondrian Investment Partners LTD, Renaissance Technologies LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Iradimed.

How do I buy shares of Iradimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iradimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $23.09.

How big of a company is Iradimed?

Iradimed has a market capitalization of $262.53 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe.View Additional Information About Iradimed.

What is Iradimed's official website?

The official website for Iradimed is http://www.iradimed.com/.

How can I contact Iradimed?

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]


MarketBeat Community Rating for Iradimed (NASDAQ IRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Featured Article: G-20

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel